1. Home
  2. IKNA vs JFB Comparison

IKNA vs JFB Comparison

Compare IKNA & JFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • JFB
  • Stock Information
  • Founded
  • IKNA 2016
  • JFB 2014
  • Country
  • IKNA United States
  • JFB United States
  • Employees
  • IKNA N/A
  • JFB N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • JFB
  • Sector
  • IKNA Health Care
  • JFB
  • Exchange
  • IKNA Nasdaq
  • JFB NYSE
  • Market Cap
  • IKNA 61.8M
  • JFB 49.5M
  • IPO Year
  • IKNA 2021
  • JFB 2025
  • Fundamental
  • Price
  • IKNA $1.36
  • JFB $5.31
  • Analyst Decision
  • IKNA Strong Buy
  • JFB
  • Analyst Count
  • IKNA 1
  • JFB 0
  • Target Price
  • IKNA $4.00
  • JFB N/A
  • AVG Volume (30 Days)
  • IKNA 95.6K
  • JFB 26.8K
  • Earning Date
  • IKNA 08-07-2025
  • JFB 08-11-2025
  • Dividend Yield
  • IKNA N/A
  • JFB N/A
  • EPS Growth
  • IKNA N/A
  • JFB N/A
  • EPS
  • IKNA N/A
  • JFB 0.00
  • Revenue
  • IKNA N/A
  • JFB $25,946,544.00
  • Revenue This Year
  • IKNA N/A
  • JFB N/A
  • Revenue Next Year
  • IKNA N/A
  • JFB N/A
  • P/E Ratio
  • IKNA N/A
  • JFB $1,367.53
  • Revenue Growth
  • IKNA N/A
  • JFB N/A
  • 52 Week Low
  • IKNA $0.97
  • JFB $3.39
  • 52 Week High
  • IKNA $1.94
  • JFB $6.50
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 56.43
  • JFB N/A
  • Support Level
  • IKNA $1.10
  • JFB N/A
  • Resistance Level
  • IKNA $1.46
  • JFB N/A
  • Average True Range (ATR)
  • IKNA 0.07
  • JFB 0.00
  • MACD
  • IKNA -0.00
  • JFB 0.00
  • Stochastic Oscillator
  • IKNA 57.58
  • JFB 0.00

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About JFB JFB CONSTRUCTION HOLDINGS

JFB Construction Holdings is a commercial and residential real estate construction and development company. It is engaged in retail corporate buildouts, multifamily community developments and luxury residential homes, with a focus on fostering long-term relationships with clients, partners, and communities. The company operates in three distinct business segments: Commercial Construction, Residential Construction, and Real Estate Development. Key revenue is generated from Commercial Construction: This segment includes all activities related to the construction of commercial properties such as office buildings, retail spaces, and industrial facilities.

Share on Social Networks: